00-0000000 false 0001840904 0001840904 2022-10-13 2022-10-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 13, 2022

 

 

ATAI LIFE SCIENCES N.V.

(Exact name of registrant as specified in its charter)

 

 

 

The Netherlands   001-40493   Not Applicable
(State or other jurisdiction of
incorporation or organization)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

c/o Mindspace

Wallstraße 16

10179 Berlin, Germany

(Address of principal executive offices) (Zip Code)

+49 89 2153 9035

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common shares, €0.10 par value per share   ATAI  

The Nasdaq Stock Market LLC

(Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07

Submission of Matters to a Vote of Security Holders.

On October 13, 2022, atai Life Sciences N.V. (the “Company”) held its general meeting of shareholders (the “General Meeting”). As of September 15, 2022, the record date for the General Meeting, there were approximately 165,875,307 common shares outstanding. Each common share is entitled to one vote on any matter presented at the General Meeting as a voting item.

The following are the voting results for the proposals considered and voted upon at the General Meeting, all of which are described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on September 19, 2022.

Proposal 1 – Adoption of Dutch statutory annual accounts for fiscal year 2021:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

83,006,479   115,004   46,960   —  

Proposal 2 – Release of each member of our board of supervisory directors and the Company’s board of managing directors from liability for the exercise of their duties:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

79,906,860   2,020,477   1,241,106   —  

Proposal 3 - Appointment of Stephen Bardin as Managing Director:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

82,427,213   696,248   44,982   —  

Based on the foregoing votes, the shareholders approved Proposals 1, 2 and 3.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ATAI LIFE SCIENCES N.V.
Date: October 14, 2022     By:  

/s/ Florian Brand

    Name:   Florian Brand
    Title:   Chief Executive Officer
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ATAI Life Sciences NV Charts.
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ATAI Life Sciences NV Charts.